Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A clinical deep-dive into the methodological concerns, enrollment biases, mineral oil placebo controversy, and generalizability gaps that temper the REDUCE-IT trial's headline 25% MACE reduction.
Read clinical reviewA deep-dive into REDUCE-IT's randomization, blinding, mineral oil placebo debate, endpoint adjudication, and statistical hierarchy, explaining how each design choice shapes interpretation of icosapent ethyl's 25% MACE reduction.
Read clinical reviewDeep-dive into cost-effectiveness analyses from the REDUCE-IT trial of icosapent ethyl (Vascepa), including cost per QALY, payer coverage, list vs net pricing, and value for individual patients.
Read clinical reviewDeep dive into REDUCE-IT follow-up analyses, durability of icosapent ethyl's cardiovascular benefit, post-trial safety signals, and what long-term data reveal beyond the original 4.9-year median.
Read clinical reviewDeep-dive into REDUCE-IT pre-specified and post-hoc subgroup analyses for icosapent ethyl (Vascepa), examining differential MACE reduction by age, sex, BMI, baseline triglycerides, race, and other clinical variables.
Read clinical reviewA plain-English deep dive into the REDUCE-IT trial: the methodology, enrollment criteria, mineral oil controversy, full results tables, and what the 25% MACE reduction means for statin-treated patients with elevated triglycerides today.
Read clinical review